Sumitomo Pharma Co., Ltd. (FRA:DPM)

Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of EUR 5.66 billion. The enterprise value is 6.90 billion.

Market Cap	5.66B
Enterprise Value	6.90B

Important Dates

The next estimated earnings date is Friday, January 30, 2026.

Earnings Date	Jan 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	397.29M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	15.77%
Float	183.27M

Valuation Ratios

The trailing PE ratio is 6.35.

PE Ratio	6.35
Forward PE	n/a
PS Ratio	2.21
PB Ratio	3.70
P/TBV Ratio	n/a
P/FCF Ratio	42.67
P/OCF Ratio	32.77
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.97, with an EV/FCF ratio of 52.04.

EV / Earnings	7.74
EV / Sales	2.80
EV / EBITDA	8.97
EV / EBIT	10.69
EV / FCF	52.04

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.99.

Current Ratio	1.36
Quick Ratio	0.83
Debt / Equity	0.99
Debt / EBITDA	1.89
Debt / FCF	11.42
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 81.47% and return on invested capital (ROIC) is 14.15%.

Return on Equity (ROE)	81.47%
Return on Assets (ROA)	9.25%
Return on Invested Capital (ROIC)	14.15%
Return on Capital Employed (ROCE)	20.16%
Revenue Per Employee	669,110
Profits Per Employee	232,537
Employee Count	3,832
Asset Turnover	0.56
Inventory Turnover	1.81

Taxes

Income Tax	-68.56M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +313.04% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+313.04%
50-Day Moving Average	11.11
200-Day Moving Average	7.18
Relative Strength Index (RSI)	71.40
Average Volume (20 Days)	201

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of EUR 2.56 billion and earned 891.08 million in profits. Earnings per share was 2.24.

Revenue	2.56B
Gross Profit	1.58B
Operating Income	672.76M
Pretax Income	822.52M
Net Income	891.08M
EBITDA	801.50M
EBIT	672.76M
Earnings Per Share (EPS)	2.24

Balance Sheet

The company has 221.67 million in cash and 1.51 billion in debt, giving a net cash position of -1.29 billion.

Cash & Cash Equivalents	221.67M
Total Debt	1.51B
Net Cash	-1.29B
Net Cash Per Share	n/a
Equity (Book Value)	1.53B
Book Value Per Share	3.85
Working Capital	415.12M

Cash Flow

In the last 12 months, operating cash flow was 172.62 million and capital expenditures -40.06 million, giving a free cash flow of 132.57 million.

Operating Cash Flow	172.62M
Capital Expenditures	-40.06M
Free Cash Flow	132.57M
FCF Per Share	n/a

Margins

Gross margin is 61.63%, with operating and profit margins of 26.24% and 34.75%.

Gross Margin	61.63%
Operating Margin	26.24%
Pretax Margin	32.08%
Profit Margin	34.75%
EBITDA Margin	31.26%
EBIT Margin	26.24%
FCF Margin	5.17%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.00%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	15.75%
FCF Yield	2.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.84
Piotroski F-Score	6